399 related articles for article (PubMed ID: 31731005)
1. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
[TBL] [Abstract][Full Text] [Related]
2. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.
Anstee QM; Neuschwander-Tetri BA; Wong VW; Abdelmalek MF; Younossi ZM; Yuan J; Pecoraro ML; Seyedkazemi S; Fischer L; Bedossa P; Goodman Z; Alkhouri N; Tacke F; Sanyal A
Contemp Clin Trials; 2020 Feb; 89():105922. PubMed ID: 31881392
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL; Ratziu V; Harrison SA; Abdelmalek MF; Aithal GP; Caballeria J; Francque S; Farrell G; Kowdley KV; Craxi A; Simon K; Fischer L; Melchor-Khan L; Vest J; Wiens BL; Vig P; Seyedkazemi S; Goodman Z; Wong VW; Loomba R; Tacke F; Sanyal A; Lefebvre E
Hepatology; 2018 May; 67(5):1754-1767. PubMed ID: 28833331
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
5. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study.
Anstee QM; Lucas KJ; Francque S; Abdelmalek MF; Sanyal AJ; Ratziu V; Gadano AC; Rinella M; Charlton M; Loomba R; Mena E; Schattenberg JM; Noureddin M; Lazas D; Goh GBB; Sarin SK; Yilmaz Y; Martic M; Stringer R; Kochuparampil J; Chen L; Rodriguez-Araujo G; Chng E; Naoumov NV; Brass C; Pedrosa MC
Hepatology; 2023 Oct; 78(4):1223-1239. PubMed ID: 37162151
[TBL] [Abstract][Full Text] [Related]
6. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
Ratziu V; Sanyal A; Harrison SA; Wong VW; Francque S; Goodman Z; Aithal GP; Kowdley KV; Seyedkazemi S; Fischer L; Loomba R; Abdelmalek MF; Tacke F
Hepatology; 2020 Sep; 72(3):892-905. PubMed ID: 31943293
[TBL] [Abstract][Full Text] [Related]
7. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.
Anstee QM; Neuschwander-Tetri BA; Wai-Sun Wong V; Abdelmalek MF; Rodriguez-Araujo G; Landgren H; Park GS; Bedossa P; Alkhouri N; Tacke F; Sanyal AJ
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):124-134.e1. PubMed ID: 37061109
[TBL] [Abstract][Full Text] [Related]
8. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
[TBL] [Abstract][Full Text] [Related]
9. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
Tacke F
Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
11. Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice.
Chen G; Yu Y; Zhu Y; Nagashimada M; Wang Y; Nagata N; Xu L
Endocrinology; 2024 May; 165(7):. PubMed ID: 38862137
[TBL] [Abstract][Full Text] [Related]
12. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
13. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
[TBL] [Abstract][Full Text] [Related]
14. A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis.
Xiao Y; Wang Y; Liu Y; Wang W; Tian X; Chen S; Lu Y; Du J; Cai W
Liver Int; 2021 Sep; 41(9):2117-2131. PubMed ID: 33894097
[TBL] [Abstract][Full Text] [Related]
15. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
Lefere S; Devisscher L; Tacke F
Expert Opin Investig Drugs; 2020 Feb; 29(2):89-92. PubMed ID: 31952447
[No Abstract] [Full Text] [Related]
16. Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
Francque SM; Hodge A; Boursier J; Younes ZH; Rodriguez-Araujo G; Park GS; Alkhouri N; Abdelmalek MF
Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285756
[TBL] [Abstract][Full Text] [Related]
17. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.
Sven M F; Pierre B; Manal F A; Quentin M A; Elisabetta B; Vlad R; Philippe HM; Bruno S; Jean-Louis J; Pierre B; Jean-Louis A
Contemp Clin Trials; 2020 Nov; 98():106170. PubMed ID: 33038502
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
19. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Newsome PN; Buchholtz K; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal AJ; Sejling AS; Harrison SA;
N Engl J Med; 2021 Mar; 384(12):1113-1124. PubMed ID: 33185364
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM; Bedossa P; Ratziu V; Anstee QM; Bugianesi E; Sanyal AJ; Loomba R; Harrison SA; Balabanska R; Mateva L; Lanthier N; Alkhouri N; Moreno C; Schattenberg JM; Stefanova-Petrova D; Vonghia L; Rouzier R; Guillaume M; Hodge A; Romero-Gómez M; Huot-Marchand P; Baudin M; Richard MP; Abitbol JL; Broqua P; Junien JL; Abdelmalek MF;
N Engl J Med; 2021 Oct; 385(17):1547-1558. PubMed ID: 34670042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
